Published in Invest Ophthalmol Vis Sci on May 01, 2016
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 10.84
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol (1989) 7.47
Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer (2002) 6.08
The future of immune checkpoint therapy. Science (2015) 5.59
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
The liver as a lymphoid organ. Annu Rev Immunol (2009) 4.03
Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology (2011) 3.52
Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol (2009) 3.27
Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 3.19
The liposome-mediated macrophage 'suicide' technique. J Immunol Methods (1989) 2.73
Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci (2003) 2.58
Insights into thymic aging and regeneration. Immunol Rev (2005) 2.55
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood (2007) 2.35
Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology (2003) 2.10
Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J Immunol (2004) 2.07
Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol (2015) 1.45
IFN-γ-independent intraocular tumor rejection is mediated by a macrophage-dependent process that leaves the eye intact. J Leukoc Biol (2012) 1.42
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res (2003) 1.41
The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res (2012) 1.39
Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci (1981) 1.28
A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci (1992) 1.21
Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res (2008) 1.17
NK and NKT cell functions in immunosenescence. Aging Cell (2004) 1.16
In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol (2010) 1.15
Age-related effects in T cell activation and proliferation. Exp Gerontol (1993) 1.15
Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res (2006) 1.13
Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. J Immunol (2011) 1.12
Characterization of an animal model of hepatic metastasis. J Gastroenterol Hepatol (1996) 1.09
HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol (2002) 1.08
The role of macrophages in Acanthamoeba keratitis. Invest Ophthalmol Vis Sci (1996) 1.08
Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res (2009) 1.07
Uveal melanoma: A pathologist's perspective and review of translational developments. Adv Anat Pathol (2014) 1.07
A new technique for implantation of tissue culture melanoma cells in a murine model of metastatic ocular melanoma. Melanoma Res (2000) 1.06
Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci (1995) 1.05
Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer (1997) 1.03
Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci (1997) 0.97
Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci (2006) 0.94
Melanoma of the eye: revealing hidden secrets, one at a time. Clin Dermatol (2015) 0.93
Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology (1995) 0.90
CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. Immunology (2007) 0.90
Uveal melanoma prognostication: from lesion size and cell type to molecular class. Can J Ophthalmol (2012) 0.89
Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res (2006) 0.89
Activated CD11b+ CD15+ granulocytes increase in the blood of patients with uveal melanoma. Invest Ophthalmol Vis Sci (2009) 0.89
NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Invest Ophthalmol Vis Sci (2011) 0.88
B16LS9 melanoma cells spread to the liver from the murine ocular posterior compartment (PC). Curr Eye Res (1999) 0.88
HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. Br J Ophthalmol (1997) 0.86
Characterization of intraocular tumors arising in transgenic mice. Invest Ophthalmol Vis Sci (1994) 0.86
Inverse correlation between expression of HLA-B and c-myc in uveal melanoma. J Pathol (1997) 0.85
Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma. Clin Exp Metastasis (2013) 0.85
Highly pigmented Tg(Grm1) mouse melanoma develops non-pigmented melanoma cells in distant metastases. Exp Dermatol (2012) 0.84
Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells. Invest Ophthalmol Vis Sci (2004) 0.84
Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Invest Ophthalmol Vis Sci (2003) 0.84
Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol (2000) 0.84
Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother (2009) 0.83
Production and renewal of murine natural killer cells in the spleen and bone marrow. J Immunol (1982) 0.82
Tg(Grm1) transgenic mice: a murine model that mimics spontaneous uveal melanoma in humans? Exp Eye Res (2014) 0.81
Inflammation, aging, and cancer vaccines. Biogerontology (2010) 0.81
Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res (1999) 0.79
Dysfunction of dendritic cells in aged C57BL/6 mice leads to failure of natural killer cell activation and of tumor eradication. Proc Natl Acad Sci U S A (2014) 0.78
NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases. Int J Cancer (2015) 0.77
Multifunctional Architectures Constructing of PANI Nanoneedle Arrays on MoS2 Thin Nanosheets for High-Energy Supercapacitors. Small (2015) 0.76
Effect of Corneal Nerve Ablation on Immune Tolerance Induced by Corneal Allografts, Oral Immunization, or Anterior Chamber Injection of Antigens. Invest Ophthalmol Vis Sci (2017) 0.75